Virtus LifeSci Biotech Clinical Trials ETF
Save
About
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U. S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
Biggest holdings
Financial Services
2.08%
Industrials
1.81%
Real Estate
1.61%
Utilities
1.07%
Real Estate
1.04%
Utilities
0.91%
Financial Services
0.84%
Similar securities
Based on sector and market capitalization
Report issue